Scope Biosciences, a deep tech spin-off from Wageningen College & Analysis, has secured a follow-on funding from SHIFT Make investments and Oost NL to advance its CRISPR-based molecular diagnostics platform.
Based by CEO Niek Savelkoul and headquartered in Wageningen, the Netherlands, Scope Biosciences has now raised a complete of €6M in seed-stage funding, combining strategic and enterprise capital investments with non-dilutive help from main European and Dutch innovation programmes.
The funding follows the corporate’s sturdy development and first vital business traction. Together with this new capital, along with a beforehand awarded €2.5M EIC Transition Grant and earlier investments, ScopeBio has secured complete funding to scale up and construct out its platform for real-world diagnostic challenges.
The spherical represents continued backing from current traders SHIFT Make investments and Oost NL. Scope Biosciences has developed its scopeDx expertise to allow diagnostics nearer to the supply, addressing challenges in each agricultural and healthcare markets the place centralised laboratories aren’t available.
Scope Biosciences: Extremely-precise, field-ready diagnostics with out proprietary {hardware}
On the coronary heart of Scope Biosciences’s mission is its next-generation CRISPR-based molecular diagnostics platform — scopeDx — that delivers ultra-precise, single-nucleotide detection in a transportable, field-ready format with out proprietary {hardware} or centralised labs.
The expertise permits earlier and more practical detection of crop ailments in agriculture, serving to to cut back losses and enhance yields, while in healthcare, it contributes to quicker and broader entry to dependable testing, particularly in areas the place centralised laboratories aren’t obtainable.
The molecular diagnostics market is experiencing vital development as demand will increase for point-of-care testing options that may function outdoors conventional laboratory settings.
From Wageningen analysis to business diagnostics platform
CEO and founder Niek Savelkoul constructed the corporate as a spin-off from Wageningen College & Analysis, leveraging deep technical experience in molecular diagnostics.
SHIFT Make investments brings sector-specific expertise in agricultural expertise investments, while Oost NL focuses on regional innovation with world relevance within the East Netherlands ecosystem.
“We’re grateful for the continued backing of SHIFT and Oost NL, and proud to have secured vital private and non-private help as we carry our expertise nearer to market,” says Niek Savelkoul, CEO and founding father of ScopeBio. “We’re scaling up, constructing out our platform, and on the point of meet real-world diagnostic challenges head-on.”
“We’re proud to supply our continued help to ScopeBio. Over the previous couple of years, we’ve got intently adopted ScopeBio’s progress in commercialising their extremely correct, on-site diagnostic platform in agriculture. We’re excited to see the crew tackling the healthcare market with the identical stage of willpower,” says Sophie van Weede, Affiliate at SHIFT Make investments.
Regional innovation hub driving world diagnostic options
ScopeBio is embedded within the vibrant innovation ecosystem of the East Netherlands area, working from the Wageningen Campus. The corporate has demonstrated business traction in agricultural diagnostics whereas increasing into healthcare functions.
“ScopeBio’s expertise aligns completely with our ambition to foster regional innovation with world relevance. We’re proud to help this pioneering firm because it enters its subsequent development section,” says Maureen Haverkamp, Funding Supervisor at Oost NL.
